On December 5, 2017 BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, reported that on this date it hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY (Press release, BioLineRx, DEC 5, 2017, View Source;p=RssLanding&cat=news&id=2321125 [SID1234522378]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Philip Serlin, Chief Executive Officer of BioLineRx, stated, "This annual event gives us the opportunity to directly meet with our investors for updates on our progress: steady advancements on our multiple clinical programs in stem cell mobilization, combination immunotherapies and acute myeloid leukemia (AML), as well as our new and novel immuno-oncology therapy. And we are pleased to feature a presentation by Dr. John DiPersio, Chief, Division of Oncology at Washington University School of Medicine, an internationally-renowned hematologist and expert on the role of CXCR4 in stem-cell mobilization and hematological malignancies. There remains a large, unmet need for cancer therapies and we remain focused on advancing programs that improve upon current treatments and the standard of care."
In addition to the keynote presentation by Dr. DiPersio on bone marrow transplantation and the role of CXCR4 in cancer, additional topics for discussion at the ongoing BioLineRx investor breakfast meeting include: (i) presentation on BL-8040 clinical development plans in immuno-oncology combinations and AML, as well as on the upcoming GENESIS Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation in multiple myeloma patients; (ii) presentation of AGI-134, the Company’s novel immuno-oncology project; and (iii) an overview of the Company’s plans and expected milestones for 2018.
BioLineRx is hosting a live webcast of the investor breakfast today between 9:00-10:30 am ET. To access the webcast, please go to the breakfast event page on BioLineRx’s website. An audio replay of the meeting will also be available for approximately three months following the meeting on the breakfast event page.